HCM is widely underdiagnosed, but the American College of Cardiology and American Heart Association hope their new guidelines can help cardiologists learn more about the potentially fatal condition and improve patient care.
Abbott’s Aveir DR leadless pacemaker, the first pacing offering of its kind to gain FDA approval, is linked to a consistent electrical performance six months after implant. Researchers tracked data from nearly 400 patients and presented their full findings in Heart Rhythm.
A team of specialists from Cleveland Clinic reviewed nearly 3,000 medications, writing that a common type 2 diabetes medication offered the most potential as an effective treatment for AFib.
Harold Litt, MD, division chief of cardiothoracic imaging and director of the Center for Advanced CT Imaging Sciences at the Perelman School of Medicine of the University of Pennsylvania, explains the role of cardiac CT in EP procedures.
Researchers examined data from 82,000 TAVR patients, focusing on echocardiography-defined PPM. They shared their results in JACC: Cardiovascular Imaging.
Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."
![Abbott’s Aveir DR leadless pacemaker, the world’s very first dual-chamber pacing solution of its kind, is associated with a “reliable” performance after six months, according to new data published in Heart Rhythm.[1]](/sites/default/files/styles/stack_views/public/2024-05/screen_shot_2024-05-10_at_11.33.50_am.png.webp?itok=MJwlIHX4)
